Skip to main content
. 2022 Jul 25;11(7):503–512. doi: 10.1302/2046-3758.117.BJR-2021-0358.R2

Fig. 5.

Fig. 5

a) The expression of runt-related transcription factor 2 (Runx2) at the tendon-bone interface at two, four, and eight weeks in each of the two groups (n = 4) using 3, 3 -diaminobenzidine (DAB) staining, and b) the proportion of Runx2-positive cells quantified at a magnification of ×400. Results are presented as mean and standard deviation (SD). *p < 0.05. c) Expression of osteocalcin (OCN) at the tendon-bone junction at two, four, and eight weeks in each of the two groups (n = 4). d) The proportion of OCN-positive cells was quantified at a magnification of ×400. Results are presented as mean and SD. *p < 0.05. NC, negative control; SLPI, secretory leucocyte protease inhibitor.